al., Progress in Growth Factor
Research, 4, 207 (1992).
2. Chen, W., et al., J. Immunol., 147, 528 (1991).
3. Rousset, F., et al., Proc. Natl. Acad. Sci. USA, 89,
1890 (1992).
4. Liu, Y., et al.
Anti Cy3+Cy5 C0992 NA NA M
504 Anti Cy3+Cy5 C0992 NA NA M
517 Nitrotyrosin N0409 NA NA P n/d n/d n/d
528 Anti Cy3+Cy5 C0992 NA NA M
552 Anti Cy3+Cy5 C0992 NA NA M
565 Phosphoserine P5747 NA NA M
566
Anti Cy3+Cy5 C0992 NA NA M
504 Anti Cy3+Cy5 C0992 NA NA M
517 Nitrotyrosin N0409 NA NA P n/d n/d n/d
528 Anti Cy3+Cy5 C0992 NA NA M
552 Anti Cy3+Cy5 C0992 NA NA M
565 Phosphoserine P5747 NA NA M
566
Anti Cy3+Cy5 C0992 NA NA M
504 Anti Cy3+Cy5 C0992 NA NA M
517 Nitrotyrosin N0409 NA NA P n/d n/d n/d
528 Anti Cy3+Cy5 C0992 NA NA M
552 Anti Cy3+Cy5 C0992 NA NA M
565 Phosphoserine P5747 NA NA M
566
JNK3/SAPK1b (K55R), inactive, KA 200 µg 13-126
Streptavidin Binding Peptide
JNK3tide 1 mg 12-528
MKK6/SKK3, active KA 10 µg 14-303
Jun
see "AP-1" above
LIMK
The Actin cytoskeleton undergoes
P1870 P y n/d n/d
525 p130CAS C0354 P y y y
526 p14 arf P2610 M y n/d n/d
527 Prox1 P0968 M y n/d y
528 Anti Cy3+Cy5 C0992 M NA NA NA
529 p19INK4d P4354 M y n/d n/d
530 p21WAF1/Cip1
1029 CDKN2A NP_478104.2 M y n/d n/d
527 p16INK4a/CDKN2 P0968 1029 CDKN2A NP_478104.2 M y n/d n/d
528 Anti Cy3+Cy5 C0992
529 p19INK4d P4354 1032 CDKN2D NP_524145.1 M y n/d n/d
530 p21WAF1/Cip1 P1484 12575
1029 CDKN2A NP_478104.2 M y n/d n/d
527 p16INK4a/CDKN2 P0968 1029 CDKN2A NP_478104.2 M y n/d n/d
528 Anti Cy3+Cy5
529 p19INK4d P4354 1032 CDKN2D NP_524145.1 M y n/d n/d
530 p21WAF1/Cip1 P1484 12575